|Authors||Im GY, Lucey MR|
|Journal||Gastroenterol Hepatol (N Y) Volume: 12 Issue: 8 Pages: 478-489|
|Publish Date||2016 Aug|
Recent advances in the treatment of alcoholic hepatitis (AH) have reinforced the utility of glucocorticoids, a treatment that has been in use for nearly 4 decades, to enhance short-term survival. As multi-institutional consortia research new therapeutic advances, this orphan disease, which afflicts younger patients and has poor outcomes, continues to be difficult to manage. AH has a protean clinical presentation and course, with various prediction models and treatment approaches that can challenge even experienced providers. This review addresses 4 key controversies and other practical issues associated with the diagnosis, prognosis, management, and treatment of patients with AH.
|Full Text||Full text available on PubMed Central|